Volume 10, Issue 5, Pages (November 2004)

Slides:



Advertisements
Similar presentations
Δ-Tocotrienol treatment is more effective against hypoxic tumor cells than normoxic cells: potential implications for cancer therapy  Akira Shibata, Kiyotaka.
Advertisements

Saikosaponin-D Enhances Radiosensitivity of Hepatoma Cells under Hypoxic Conditions by Inhibiting Hypoxia-Inducible Factor-1α Cell Physiol Biochem 2014;33:37-51.
Volume 14, Issue 3, Pages (September 2006)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Oncolytics
Volume 128, Issue 7, Pages (June 2005)
Volume 11, Issue 2, Pages (February 2005)
Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy  Che-Hsin Lee, Chao-Liang Wu, Yun-Sheng.
Volume 12, Issue 3, Pages (July 2015)
Molecular Therapy - Oncolytics
Molecular Therapy - Oncolytics
Volume 9, Issue 6, Pages (June 2004)
Volume 138, Issue 5, Pages e2 (May 2010)
Volume 26, Issue 2, Pages (February 2018)
Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes  Dirk S. Steinwaerder, Cheryl A. Carlson,
Volume 21, Issue 9, Pages (September 2013)
Volume 18, Issue 2, Pages (February 2010)
Volume 10, Issue 6, Pages (December 2004)
Molecular Therapy - Oncolytics
Volume 75, Issue 12, Pages (June 2009)
M.Brandon Parrott, Michael A. Barry  Molecular Therapy 
Volume 20, Issue 12, Pages (December 2012)
Volume 7, Issue 2, Pages (February 2003)
Volume 18, Issue 3, Pages (March 2010)
Molecular Therapy - Oncolytics
Volume 7, Issue 1, Pages (January 2003)
Volume 9, Issue 4, Pages (April 2004)
Anke Sparmann, Dafna Bar-Sagi  Cancer Cell 
Molecular Therapy - Oncolytics
Volume 22, Issue 1, Pages (January 2014)
Volume 11, Issue 4, Pages (April 2005)
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity  Xinping Fu, Armando Rivera, Lihua.
HDAC5, a Key Component in Temporal Regulation of p53-Mediated Transactivation in Response to Genotoxic Stress  Nirmalya Sen, Rajni Kumari, Manika Indrajit.
Volume 8, Issue 3, Pages (September 2003)
Volume 9, Issue 6, Pages (June 2004)
Molecular Therapy - Nucleic Acids
Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models  Fabrice Le Boeuf, Simon Gebremeskel,
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis
Volume 23, Issue 4, Pages (April 2015)
Volume 23, Issue 4, Pages (April 2015)
Volume 12, Issue 5, Pages (November 2005)
Volume 12, Issue 2, Pages (August 2005)
Volume 16, Issue 6, Pages (June 2008)
Volume 12, Issue 5, Pages (November 2005)
Thomas S. Griffith, Elizabeth L. Broghammer  Molecular Therapy 
Volume 17, Issue 2, Pages (February 2009)
Volume 10, Issue 4, Pages (October 2004)
Volume 13, Issue 5, Pages (May 2006)
Volume 20, Issue 1, Pages (January 2012)
Volume 20, Issue 5, Pages (May 2012)
Lipopolysaccharide Potentiates the Effect of Hepatocyte Growth Factor upon Replication in Lung, Thyroid, Spleen, and Colon in Rats in Vivo  Cuihua Gao,
Volume 18, Issue 5, Pages (May 2010)
Volume 6, Issue 3, Pages (September 2002)
Fan Yang, Huafeng Zhang, Yide Mei, Mian Wu  Molecular Cell 
Volume 26, Issue 1, Pages (January 2018)
Volume 21, Issue 4, Pages (April 2013)
Volume 12, Issue 6, Pages (December 2005)
Volume 10, Issue 6, Pages (December 2004)
Volume 12, Issue 1, Pages (July 2005)
Volume 18, Issue 3, Pages (March 2010)
Volume 23, Issue 3, Pages (March 2015)
Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma  Chien-Kuo.
Molecular Therapy - Oncolytics
Cowpox Virus: A New and Armed Oncolytic Poxvirus
Yoshinori Aragane, Akira Maeda, Chang-Yi Cui, Tadashi Tezuka 
Volume 16, Issue 10, Pages (October 2008)
Volume 20, Issue 6, Pages (June 2012)
Volume 20, Issue 4, Pages (April 2012)
Volume 15, Issue 2, Pages (February 2007)
Volume 12, Issue 5, Pages (November 2005)
Presentation transcript:

Volume 10, Issue 5, Pages 938-949 (November 2004) Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor  Won-Kyung Cho, Young Rim Seong, Yeune Hee Lee, Min Ji Kim, Kyung-Sun Hwang, Jinsang Yoo, Seeyoung Choi, Cho-Rok Jung, Dong-Soo Im  Molecular Therapy  Volume 10, Issue 5, Pages 938-949 (November 2004) DOI: 10.1016/j.ymthe.2004.07.023 Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

FIG. 1 Construction of and analysis of E1A expression from oncolytic adenoviruses. (A) HepG2 cells were transfected with the indicated plasmids harboring luciferase as a reporter gene under the transcriptional control of the E1A promoter or SV40 minimal promoter linked to 5 × HRE from the human VEGF promoter (5 × VEGF-HRE-pSV40 min) and grown for 24 h under normoxia. Cells were further incubated under normoxic (20% O2) or hypoxic (1% O2) conditions for 16 h, before the reporter assay was performed. Data are the means ± SD of three independent experiments in duplicate. (B) Replication-competent or -defective adenoviruses constructed in this study and Ad.Δ55.E1A (dl1520; Onyx-015) are schematically illustrated. ψ, packaging signal; pA, polyadenylation signal. (C) Huh-7 cells were infected with Ad.E1A.Δ55, Ad.Δ55.HRE, or Ad.stuffer.HRE.Δ55 at an m.o.i. of 20 and exposed to normoxia or hypoxia for 20 h before the cell lysates were subjected to Western blot analysis with the indicated antibodies. Molecular Therapy 2004 10, 938-949DOI: (10.1016/j.ymthe.2004.07.023) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

FIG. 2 Oncolytic effect of Ad.Δ55.HRE on parental Huh-7 and Huh-7 hepatoma cells constitutively expressing HIF-1α. (A) Clear cell lysates of parental Huh-7 and Huh-7 cells constitutively expressing HIF-1α (Huh-7/HIF-1α) were immunoprecipitated (IP) with anti-Flag antibody followed by immunoblotting with anti-Flag antibody. Molecular mass markers in kDa are shown at the left. (B) Huh-7 or Huh-7/HIF-1α cells were infected with Ad.HRE.luc (Fig. 1B) encoding luciferase as a reporter gene under the control of the 5×VEGF-HRE-pSV40 min at an m.o.i. of 1. Luciferase activity in equivalent cell lysates was determined at 20 h posttransduction. Data are the means ± SD of three independent experiments in duplicate. (C) Huh-7 and Huh-7/HIF-1α cells were infected with Ad.Δ55.HRE (lanes 2, 4, 6, and 8) or Ad.E1A.Δ55 (lanes 1, 3, 5, and 7) at the indicated m.o.i. and incubated under normoxia or hypoxia for 4 days. Oncolytic effect of the adenoviruses was evaluated by staining viable cells with crystal violet. The experiment was repeated more than twice and a representative is shown. (D) Huh-7 cells were infected with Ad.Δ55.HRE or Ad.E1A.Δ55 at an m.o.i. of 0.5. Cells were harvested at the indicated times. Adenoviruses from the culture media and the infected cells were titered on a 293 plaque assay. Data are the means ± SD of two independent experiments. Molecular Therapy 2004 10, 938-949DOI: (10.1016/j.ymthe.2004.07.023) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

FIG. 3 Oncolytic effects of Ad.Δ55.HRE on PC-3 prostate, Panc-1, and AsPC-1 pancreatic tumor cells. (A) PC-3 tumor cells were mock infected or infected with Ad.E1A.Δ55 or Ad.Δ55.HRE at an m.o.i. of 20 and incubated under normoxia or hypoxia for 20 h before Western blot analysis with the indicated antibodies. (B) PC-3 tumor cells were mock infected or infected with Ad.E1A.Δ55 or Ad.Δ55.HRE at the indicated m.o.i. and incubated for 4 days under normoxia, and viable cells were stained with crystal violet. (C) Panc-1 and AsPC-1 tumor cells were infected with Ad.Δ55.HRE (lanes 2 and 4) or Ad.E1A.Δ55 (lanes 1 and 3) at the indicated m.o.i. and incubated for 4 days under normoxia, and survival cells were stained with crystal violet. The experiment was repeated more than twice and a representative is shown. Molecular Therapy 2004 10, 938-949DOI: (10.1016/j.ymthe.2004.07.023) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

FIG. 4 Oncolytic effects of Ad.Δ55.HRE on HepG2 hepatoma and A549 lung tumor cells. (A) The tumor cells were infected with the indicated adenoviruses at an m.o.i. of 20, incubated for 20 h under normoxic or hypoxic conditions, and lysed for Western blot analysis with the indicated antibodies. (B) HepG2 cells were infected with the indicated adenoviruses at an m.o.i. of 1 and incubated for 4 days under normoxic or hypoxic conditions, before adenoviruses from the culture media and the infected cells were titered on a 293 plaque assay. Data are the means ± SD of three independent experiments. (C) HepG2 or A549 cells were infected with Ad.E1A.Δ55 or Ad.Δ55.HRE at the indicated m.o.i. and incubated under normoxic or hypoxic conditions for 4 days, before cells were stained with crystal violet. The experiment was repeated more than twice and a representative is shown. Molecular Therapy 2004 10, 938-949DOI: (10.1016/j.ymthe.2004.07.023) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

FIG. 5 Cytotoxic effects of Ad.Δ55.HRE and Ad.E1A.Δ55 on normal fibroblast cells. (A) MRC-5 and IMR-90 fibroblast cells were mock infected (lanes 1, 4, 7, and 10) or infected with Ad.Δ55.HRE (lanes 3, 6, 9, and 12) or Ad.E1A.Δ55 (lanes 2, 5, 8, and 11) at an m.o.i. of 20 and incubated for 20 h under normoxic or hypoxic conditions before cell lysates were immunoblotted with the indicated antibodies. (B) MRC-5 and IMR-90 cells were mock infected or infected with Ad.Δ55.HRE (lanes 2, 4, 6, and 8) or Ad.E1A.Δ55 (lanes 1, 3, 5, and 7) at the indicated m.o.i. and incubated under normoxic or hypoxic conditions for 4 days. Cytotoxic effect of the viruses was evaluated by staining viable cells with crystal violet. The experiment was repeated more than twice and a representative is shown. Molecular Therapy 2004 10, 938-949DOI: (10.1016/j.ymthe.2004.07.023) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

FIG. 6 In vivo antitumor activity of Ad.Δ55.HRE in PC-3 prostate tumor-bearing nude mice and long-term survival analysis. PC-3 tumor xenografts developed in nude mice were intratumorally injected daily for 5 consecutive days with 2 × 108 pfu of Ad.E1A.Δ55 (n = 4), Ad.Δ55.HRE (n = 5), or PBS (n = 4) as a control. (A) Tumor growth and (B) body weight of the mice were measured at the indicated times. Data are presented as the mean tumor volumes or body weights ± SD and are indicative of one of two such experiments with a similar outcome. (C) In the experiments described for (A), the fraction of animals alive within the different treatment groups was plotted against days after xenografting. Molecular Therapy 2004 10, 938-949DOI: (10.1016/j.ymthe.2004.07.023) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

FIG. 7 In vivo antitumor activity of Ad.Δ55.HRE in MDA-MB-435 tumor-bearing mice and immunohistochemical analysis of E1A, hexon, and HIF-1α expression in tumor xenografts. (A) MDA-MB-435 xenografts were established subcutaneously in the dorsal flanks of Balb/c nude mice. Once tumors reached about 150–200 mm3 in volume, they were intratumorally injected daily for 5 consecutive days with PBS (n = 6) or 2 × 108 pfu of Ad.E1A.Δ55 (n = 6) or Ad.Δ55.HRE (n = 7). Tumor growth was measured at the indicated times. Data are presented as the mean tumor volumes ± SD. (B) Animals in (A) were sacrificed at 37 days after initial treatment, and tumors were excised and subjected to immunohistochemical analysis using anti-E1A and anti-hexon antibodies as described under Materials and Methods. The numbers of tumor cells containing E1A or hexon proteins, which appeared as brown spots, were counted in three different fields of tumor samples from mice at × 200 magnification and averaged, respectively. Representative photographs with the mean numbers of the immunostained E1A or hexon proteins are shown. (C) Tumors were excised from PC-3 and MDA-MB-435 xenografts developed in nude mice and subjected to immunostaining with anti-HIF-1α antibody. Brown-stained cells are positive for the expression of HIF-1α. Controls are tumor tissues incubated without primary antibody. Representative photographs (original magnification × 200) are shown. Molecular Therapy 2004 10, 938-949DOI: (10.1016/j.ymthe.2004.07.023) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions